In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (12/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Roche has funneled its IP in antibiotics, antifungals and dermatology into spin-off Basilea Pharmaceutica. Building on technology invented by NASA to detect life on Mars, BioLuminate Inc. will develop a diagnostic probe to measure breast cancer indicators after initial screening has revealed a region of concern. Integrative Proteomics Inc. aims to be a dominant player in proteomics with its platform for high-throughput protein expression and purification, protein-protein interaction and 3-dimensional structure determination. invivodata inc. is offering a money-back guarantee to users of its invivosystem, a handheld method for recording, managing and analyzing real-time patient experience data during pharmaceutical clinical trials. Metazoa Systems Inc. has launched a web portal offering research management tools for life science researchers. Aventis CropScience spin-off Scynexis Chemistry & Automation Inc. will provide drug discovery chemistry services for pharmaceutical and other life sciences clients.

You may also be interested in...



Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."

In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients

BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.

Related Companies

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel